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Background: Chronic kidney disease (CKD) with edema is a common clinical problem resulting from defects
in water and solute excretion. Furosemide is the drug of choice for treatment. In theory, good perfusion
and albumin are required for the furosemide to be secreted at the tubular lumen. Thus, in the situation of
low glomerular filtration rate (GFR) and hypoalbuminemia, the efficacy of furosemide alone might be limited.
There has been no study to validate the effectiveness of the combination of furosemide and albumin in this
condition.
Methods: We conducted a randomized controlled crossover study to compare the efficacy of diuretics
between furosemide alone and the combination of furosemide plus albumin in stable hypoalbuminemic
CKD patients by measuring urine output and sodium. The baseline urine output/sodium at 6 and 24 hours
were recorded. The increment of urine output/sodium after treatment at 6 and 24 hours were calculated by
using post-treatment minus baseline urine output/sodium at the corresponding period.
Results: Twenty-four CKD patients (GFR = 31.0 ± 13.8 mL/min) with hypoalbuminemia (2.98 ± 0.30 g/dL) were
enrolled. At 6 hours, there were significant differences in the increment of urine volume (0.47 ± 0.40 vs 0.67± 0.31 L,
P< 0.02) and urine sodium (37.5 ± 29.3 vs 55.0± 26.7 mEq, P<0.01) between treatment with furosemide alone and with
furosemide plus albumin. However, at 24 hours, there were no significant differences in the increment of urine volume
(0.49 ± 0.47 vs 0.59± 0.50 L, P = 0.46) and urine sodium (65.3 ± 47.5 vs 76.1 ± 50.1 mEq, P = 0.32) between the two
groups.
Conclusion: The combination of furosemide and albumin has a superior short-term efficacy over furosemide alone in
enhancing water and sodium diuresis in hypoalbuminemic CKD patients.
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Chronic kidney disease (CKD) is a common problem in
clinical practice. The deterioration of renal function
impairs salt and water clearance leading to edema and
volume overload. The treatment of choice in this situ-
ation is administration of a diuretic especially a high po-
tency loop diuretic to enhance free water and salt
clearance.
Furosemide is one of the most commonly used high
potency loop diuretics in clinical practice. It is an or-
ganic acid, which is highly bound to protein (mostly
forming furosemide-albumin complex), which reaches
the proximal tubular epithelial cells and is secreted in
active free form by the anion transporter into the tubu-
lar lumen. The site of action of furosemide is the thick
ascending limb of the loop of Henle. The mechanism of
action is to inhibit active chloride transport at the Na-K-
2Cl channel which leads to impaired sodium and chlor-
ide reabsorption resulting in natriuresis and free water
clearance [1-6].
Despite the high potency of natriuresis, diuretic resist-
ance can still occur. The proposed mechanisms of diur-
etic resistance are as follows. Firstly, a decline in renal
perfusion decreases the rate of drug delivery to its site of
action [2,7]. Secondly, severe hypoalbuminemia impairs
furosemide secretion into the tubular lumen [8-10].
Thirdly, the accumulation of organic acids, such as hip-
purate in renal failure state, may compete with furosem-
ide secretion into the tubular lumen via the organic
anion transport system at the proximal tubule so de-
creasing the diuretic activity of furosemide [11-15].
Hypoalbuminemia impairing furosemide secretion was
demonstrated by Inoue et al. in 1987 [9]. The studies
have shown that analbuminemic rats have a high resist-
ance to furosemide alone compared with the combin-
ation of furosemide and albumin which provides more
urine output and sodium excretion.
The potential effect of the combination of furosemide
and albumin is still controversial. Fliser et al. [16] have
found that the effect of the combination of furosemide
and albumin can significantly, but modestly increase
urine output and sodium excretion in nephrotic syn-
drome patients. In contrast, others failed to demonstrate
this effect [17,18]. In studies of hypoalbuminemic cir-
rhotic patients, one study has shown the benefit of the
combination [19] while others have shown no significant
differences in water and sodium excretion between fur-
osemide alone and the combination of furosemide plus
albumin [20,21].
Although there is a common usage of the combination
of furosemide and albumin in hypoalbuminemic patients
in clinical practice, whether there is any significant bene-
fit of this combination for the treatment of edema in
hypoalbuminemic patients especially in patients withchronic kidney disease is still unknown. Due to the high
price of albumin and allergic reactions which can occur
to it [22,23], we conducted a randomized controlled
crossover study to compare the efficacy of diuresis be-
tween furosemide alone and the combination of fur-
osemide plus albumin for the treatment of edema in
stable hypoalbuminemic chronic kidney disease patients
by measuring urine output and urine sodium.
Subjects and methods
Subjects
Twenty-four patients with stable chronic kidney disease
(no fluctuation of GFR>10% in two months) who pre-
sented with edema (pretibial pitting edema from physical
examination) and low serum albumin were enrolled in this
study. CKD patients were defined as patients who have
GFR<60 mL/min per 1.73 m2 and low serum albumin was
defined as serum albumin<3.5 g/dL. Exclusion criteria
were patients with GFR<10 mL/min per 1.73 m2, heavy
proteinuria (24-hour urine protein> 3.5 g/d), critically ill
patients such as congestive heart failure, acute renal fail-
ure, shock, on respirator and/or previous history of fur-
osemide usage within two weeks. The study protocol
was approved by the Ethics Committee on Human Stud-
ies at Ramathibodi Hospital, Bangkok, Thailand (ID 06-
52-18). Written informed consent was obtained from
each patient. The study protocol was also registered with
the Australian New Zealand Clinical Trials Registration
(ANZCTR 12611000480987).
Methods
Patient characteristics were documented. Antihypertensive
agents, including angiotensin converting enzyme inhibitor
(enalapril), angiotensin receptor blocker (candesartan),
atenolol, doxazosin and/or hydralazine, were used to
control blood pressure. Their dosage was kept un-
changed throughout the study. GFR was calculated by
the modified diet in renal disease (MDRD) equation
(186 ×Cr(−1.154) × age(−0.203), and for female multiply by
0.742). Diet with Na = 50 mEq/d and K = 60 mEq/d was
designed by a nutritionist and was provided to each patient
during the studies. Patients were randomly assigned first to
have furosemide alone or the combination of furosemide
plus albumin. The body weight, height, and blood pressure
were recorded. Blood samples were initially collected from
each patient for determination of electrolytes, albumin,
blood urea nitrogen and creatinine (at time 0) and then at
6, 24, 30, and 48 hours. Urine was collected to determine
the volume and electrolytes at 6 and 24 hours before and
after the intervention. Furosemide (40 mg) alone or the
combination of furosemide and albumin (10 g of 20%
human albumin) was given intravenously at time 24 hours
(Figure 1). The batch of salt-poor human albumin used in
this study (ZenalbW 20, Bio Products Laboratory, Herts,
Figure 1 This scheme shows the steps of the experiment. (A) Shows diagram of cross over study. (B) Shows timeline for blood and urine
collections before and after intervention. Pointing down arrow = Blood collection, Pointing up arrow = Spot urine collection. Light rectangular
box = Urine collection before intervention. Dark rectangular box = Urine collection after intervention.
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Patients were advised to take oral fluids as much as their
urine output. After they had completed the first part, they
were assigned to have the second part at least two weeks
apart (Figure 1). Serum electrolyte, BUN, and creatinine
levels were determined using a Technicon Auto Analyzer.
The increment of urine output after treatment at each
period (6 or 24 hours) was calculated by using post-
treatment urine output minus pre-treatment urine output
at each corresponding period. Also, the increment of urine
sodium was calculated by using the same method.
Statistical analysis
Statistical analysis was performed using SPSS version
16.0. The mean± SD was calculated for patient charac-
teristics and diagnostic measures. The number of the
sample size was hypothesized based on the power and
sample size calculation from the difference of urine out-
put and urine sodium, with α = 0.05 and power = 80%,
from a previous study [16]. The calculation revealed 20
patients. The statistical significance of the difference in
these measures was examined by using Mann Whitney
U- test or t test (continuous variable and depends on thedata distribution) and chi-square or Fishers’ exact test
(categorical variable). The difference was considered sig-
nificant if the P-value < 0.05. For baseline 24-hour urine
protein data, they did not show a normal distribution, so
we used median and interquartile range for the calcula-
tion. A nonparametric test was used to evaluate signifi-
cant differences between groups.Results
Twenty-four stable chronic kidney patients with hypoal-
buminemia were included in this study. There were 11
male and 13 female patients. The average GFR in this
study was 31.0 ± 13.8 mL/min and the mean serum albu-
min was 2.98 ± 0.30 g/dL. The other baseline characteris-
tics before intervention have been summarized in
Table 1.
There were no differences in baseline body weight,
blood pressure, calculated GFR, serum albumin, urine
protein, urine output and urine sodium at 6 and 24 hours
between the furosemide alone (F) and the furosemide
plus albumin (F +A) group before the intervention
(Table 2).
Table 1 Baseline characteristics of the patients
Numbers 24
Age (years) 66.4 ± 12.8
Males : Females 11 : 13
Weight (kgs) 65.6 ± 11.3
Height (cms) 164 ± 9
BMI (kgs/m2) 24.4 ± 4.3
Systolic blood pressure (mmHg) 131.5 ± 6.2
Diastolic blood pressure (mmHg) 79.6 ± 5.5
Serum creatinine (mg/dL) 2.18 ± 0.79
Calculated GFR (mL/min/1.732) 31.0 ± 13.8
Serum albumin (g/dL) 2.98 ± 0.30 (2.32-3.46)
Serum sodium (mEq/L) 139 ± 2.7
Serum potassium (mEq/L) 4.3 ± 0.46
Serum chloride (mEq/L) 104 ± 3.2
Serum bicarbonate (mEq/L) 25.9 ± 3.6
24-hour urine protein (g/d) 0.56† (0.01-3.1)
Causes of chronic kidney disease Numbers
Hypertension 7
Diabetes mellitus 6
Autosomal dominant polycystic kidney disease 4




† Median (ranges), BMI = Body mass index, GFR = Glomerular filtration rate.
Table 2 Baseline parameters before each intervention in chro
Furosemide
Mean± SD
Weight (kgs) 65.6 ± 11.4
Blood pressure (mmHg) systolic 131.2 ± 6.0
diastolic 79.3 ± 5.3
Calculated GFR (mL/min/1.732) 31.5 ± 14.6
Serum albumin (g/dL) 2.99 ± 0.30
24-hr urine protein (g/d)† 0.45
Urine volume at 6 hours (L) 0.43 ± 0.32
Urine volume at 24 hours (L) 1.95 ± 0.82
Urine sodium at 6 hours (mEq) 17.4 ± 17.7
Urine sodium at 24 hours (mEq) 81.5 ± 46.0
Urine potassium at 6 hours (mEq) 6.89 ± 5.2
Urine potassium at 24 hours (mEq) 37.9 ± 12.2
† Median.
†† Evaluated by nonparametric test.
GFR = Glomerular filtration rate SD = standard deviation.
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ences in blood pressure and calculated GFR between both
groups (Table 3). As expected, there were significant differ-
ences in serum albumin at 6 hours (2.98±0.30 vs
3.46±0.42 g/dL, P < 0.01) and at 24 hours (2.97±0.31 vs
3.42±0.41 g/dL, P < 0.01) between the furosemide alone
and the furosemide plus albumin group (Table 3).
There were significant increases in urine output in post-
treatment compared to pre-treatment in both interven-
tions at 6 hours (0.43±0.32 vs 0.90± 0.35 L, P <0.01 for F
group, and 0.40±0.23 vs 1.07± 0.34 L, P < 0.01 for F + A
group) and at 24 hours (1.95 ± 0.82 vs 2.44 ± 0.74 L,
P <0.01 for F group, and 1.89 ± 0.59 vs 2.47 ± 0.60 L,
P < 0.01 for F +A group) (Figure 2A). Also, there
were significant increases in urine sodium in post-
treatment compared to pre-treatment in both inter-
ventions at 6 hours (17.4 ± 17.7 vs 54.9 ± 31.6 mEq,
P < 0.01 for F group, and 15.8± 13.6 vs 70.8± 31.3 mEq,
P< 0.01 for F +A group) and at 24 hours (81.5 ± 46.0 vs
146.8 ± 59.9 mEq, P< 0.01 for F group, and 78.3± 39.2 vs
154.4 ± 42.2 mEq, P< 0.01 for F +A group) (Figure 2B).
The increments of urine output and urine sodium of
each intervention (post-treatment minus pre-treatment
urine output/sodium at each corresponding period) were
compared (Figure 3). At 6 hours, there were significant dif-
ferences in the increment of urine volume (0.47±0.40 vs
0.67±0.31 L, P<0.02) and urine sodium (37.5 ± 29.3 vs
55.0 ± 26.7 mEq, P<0.01) between treatments with fur-
osemide alone and with furosemide plus albumin respect-
ively (Figures 3A and B). However, at 24 hours, there were
no significant differences in the increment of urine volume
(0.49±0.47 vs 0.59± 0.50 L, P = 0.46) and urine sodiumnic kidney disease patients
Furosemide + Albumin P-value
Mean± SD
65.7 ± 11.5 0.83
131.8 ± 6.5 0.27
79.9 ± 5.9 0.33
30.5 ± 13.1 0.19
2.97 ± 0.30 0.31
0.56 0.27††
0.40 ± 0.23 0.58
1.89 ± 0.59 0.62
15.8 ± 13.6 0.32
78.3 ± 39.2 0.52
6.83 ± 3.99 0.94
37.4 ± 13.3 0.87
Table 3 Comparison of blood pressure, renal function, serum albumin, and urine sodium and potassium after
treatment with furosemide alone or with the combination of furosemide plus albumin in chronic kidney disease
patients
Furosemide Furosemide + Albumin P-value
Mean± SD Mean± SD
Blood pressure (mmHg)
6 hours systolic 132.0 ± 5.1 132.4 ± 6.2 0.60
diastolic 80.1 ± 5.3 80.6 ± 5.3 0.52
24 hours systolic 131.6 ±4.6 132.0 ±5.6 0.60
diastolic 79.7 ± 5.3 80.2 ± 5.5 0.57
Calculated GFR (mL/min/1.732)
6 hours 27.8 ± 12.6 27.2 ± 10.5 0.64
24 hours 29.1 ± 12.3 28.3 ± 11.3 0.23
Serum albumin (g/dL)
6 hours 2.98 ± 0.30 3.46 ± 0.42 < 0.01
24 hours 2.97 ± 0.31 3.42 ± 0.41 < 0.01
Urine volume at 6 hours (L) 0.90 ± 0.35 1.07 ± 0.34 0.02
Urine volume at 24 hours (L) 2.44 ± 0.74 2.47 ± 0.60 0.81
Urine sodium at 6 hours (mEq) 54.9 ± 31.6 70.8 ± 31.3 < 0.01
Urine sodium at 24 hours (mEq) 146.8 ± 59.9 154.4 ± 42.2 0.53
Urine potassium at 6 hours (mEq) 14.7 ± 8.0 18.0 ± 8.9 0.03
Urine potassium at 24 hours (mEq) 40.5 ± 10.0 40.3 ± 7.4 0.95
GFR = Glomerular filtration rate SD = standard deviation.
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groups (Figures 3A and B).
After the intervention, there were also significant dif-
ferences in urine potassium at 6 hours (14.7 ± 8.0 vs
18.0 ± 8.9 mEq, P = 0.03), but not at 24 hours, between
both groups (Table 3).
There were no adverse events such as congestive heart
failure, hypertension, or allergic reaction to human albu-
min/furosemide after both treatments in this study.
Discussion
In this study, we focused to compare the efficacy of diure-
tics between furosemide alone and the combination of fur-
osemide plus albumin in stable hypoalbuminemic chronic
kidney disease patients with clinical edema and without
nephrotic range proteinuria. The results of our study show
the short-term beneficial effect (at 6 hours) of the combin-
ation of furosemide plus albumin over furosemide alone in
natriuresis and diuresis in these patients. This may imply
that, in the situation of diuretic resistance, CKD patients
with low serum albumin and fluid overload may receive
more benefits from this combination regimen.
At 24 hours after treatment, the results of the study did
not show the beneficial effect of the combination treat-
ment over furosemide alone. These data are similar to the
results studied by Fliser et al. [16]. They found that the su-
perior effect of one single dose of the combination offurosemide plus albumin over furosemide alone is found
in only the first 8 hours after treatment. This has also been
noted in other studies [24]. This could possibly be due to
the short duration of action of furosemide. Furosemide is
a short half-life diuretic (1–2 hours) [25,26]. A significant
natriuresis and free water clearance is noted during the
6-hour period that the diuretic is acting. However, sodium
excretion gradually falls down during the remaining
18 hours of the day, because the associated volume deple-
tion leads to the activation of the sodium-retaining
mechanism [27]. Our findings suggest that combination
treatment increases the natriuretic potency of furosemide
at least at submaximal doses, but does not directly address
the issue of whether the same is still true at maximal does
of furosemide. Thus, one single dose of the combination
of furosemide plus albumin might not be adequate to
show the beneficial effect over furosemide alone at
24 hours. Multiple administrations or an increased dose of
diuretic may be required to maximize its potency.
Another issue deserving attention may be represented by
the finding of a decrease of about 10% in glomerular filtra-
tion rate found at 6 hours after treatment in both groups
of patients (please compare the calculated GFR finding in
Table 2 versus Table 3). This entails that a strictly diuretic
strategy in this category of patients (with moderate pro-
teinuria and edema in the absence of oliguria) is encum-
bered by the risk of inducing a further fall in renal supply
Figure 2 A. Comparison of urine volume between pre- and post-treatment with furosemide alone or the combination of furosemide plus
albumin in all chronic kidney disease patients. (B). Comparison of urine sodium between pre- and post-treatment with furosemide alone or the
combination of furosemide plus albumin in all chronic kidney disease patients. Gray box = Pre-treatment, Black box = Post-treatment.
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Since we did not have a third study arm with albumin infu-
sion alone, the issue of whether the simple adjunct of intra-
venous albumin alone is able to induce an increase in
diuresis, compared to basal urine volume, in this group of
patients cannot be answered.
It should be noted that the rise of serum albumin after
human albumin administration in this study is greater
than that observed in other studies (Table 3). This could
possibly be due to the degree of severity of nephrotic
syndrome in most other studies. The amount of protein-
uria was high, more than 10 g/d (mean) in some studies
[16,17]. After human albumin administration, most of
the administrated albumin is likely to be lost in the urine
and possibly into the interstitial space. In this study, the
median (and range) of proteinuria was 0.5 g/d (0.01-
3.1 g/d) which is relatively low compared to other stud-
ies. Therefore, it could be expected that the rise of
serum albumin in this study should be greater thanother studies. Secondly, serum albumin in this study was
co-administered with furosemide which caused volume
contraction from diuresis. The volume contraction can
affect the serum albumin concentration. This can also
be observed by the rise of the mean hematocrit of the
patients from 32.8 ± 3.2% to 35.8 ± 3.3% (data not
shown). Thirdly, our typical Asians’ body weight is much
lower than Caucasians’ body weight. In this study, the
mean body weight was 65.6 ± 11.4 kgs while the mean
body weight of the western population in one study was
90 ± 17.4 kgs [20]. These great differences (2:3) can affect
the differences in intravascular volume and the changes
in serum albumin concentration after treatment in each
population.
The concept of hypoalbuminemia resulting in defect-
ive secretion of furosemide has been shown in studies by
Inoue et al. [9]. They have demonstrated the mechanism
of diuretic resistance in analbuminemic rats (NAR) and
hypoalbuminemic patients. The studies have shown that
Figure 3 A. Comparison of the increment of urine volume after
treatment with furosemide alone or with the combination of
furosemide plus albumin at 6 and 24 hours in all chronic kidney
disease patients. (B). Comparison of the increment of urine sodium
between after treatment with furosemide alone or with the
combination of furosemide plus albumin at 6 and 24 hours in all
chronic kidney disease patients. Gray box = Furosemide, Black box=
Furosemide + Albumin.
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increases in normal rats but fails to increase in NAR.
However, when administered with both furosemide and
albumin, the urine volume in NAR was increased almost
three times compared to that of normal rats. They con-
cluded that the binding of furosemide to circulating al-
bumin might be important for the efficient delivery of
drugs to the site for their diuretic action. They also
demonstrated the efficacy of furosemide and albumin in
16 hypoalbuminemic patients with resistance to fur-
osemide (20–60 mg). The diagnosis of the patients
included liver cirrhosis, malignancy and chronic renal
failure which had serum albumin ranging from 1.5 –
3.5 g/dL. They concluded that administration of fur-
osemide and albumin enhanced diuresis in NAR, but in
hypoalbuminemic patients a well-controlled experimen-
tal study should be performed.Later on, several studies have been performed, mostly
in diuretic resistance patients by using a model of
patients with nephrotic syndrome and cirrhosis. Fliser
et al. [16] studied the efficacy of the combination of fur-
osemide and albumin in 9 patients with nephrotic syn-
drome. The study was a randomized, double-blind,
placebo-controlled, crossover trial. Patients had neph-
rotic range proteinuria with a mean serum albumin level
of 3.0 ± 0.23 g/dL. Most patients had renal function
within the normal range (mean GFR of 105 ± 9 mL/min/
1.73 m2). The results showed modest, but significant
increases of cumulative sodium, volume excretion in the
combination groups. These results implied that the com-
bination of furosemide and albumin had enhanced diur-
esis in patients with nephrotic range proteinuria and
normal renal function. Another study was performed in
8 nephrotic syndrome patients with serum albumin ran-
ging from 1.1-2.2 g/dL and impaired renal function
(serum creatinine 1.2-2.39 mg/dL). The results showed
no significant increase in urine volume and sodium ex-
cretion in all patients. They did not support the use of
albumin in treatment of patients with nephrotic syn-
drome and supported the mechanism of intratubular al-
bumin that blunts furosemide response [28].
In cirrhotic patients, several studies have demon-
strated the efficacy of the combination of furosemide
and albumin. Gentilini et al. [19] conducted a rando-
mized, controlled trial to assess the effect of albumin on
diuresis response in patients with cirrhosis. The results
showed a favourable effect of the combination of these
two for the treatment of cirrhotic patients with ascites.
They did not mention about the renal function of the
patients. Studies by Chalasani et al. [20] in 13 clinically
stable cirrhotic patients, with serum creatinine less than
2 mg/dL and 24-hour urine protein less than 100 mg/d,
showed a minimal increase in 6-hour urine volume and
urine sodium, but there was no statistical significance. A
meta-analysis by Rowland et al. [29] has concluded that
the effect of the combination of these two is still contro-
versial, but may provide benefit in some selected
patients who have recalcitrant edema or ascites or those
with severe hypoalbuminemia.
Furosemide is an organic acid, highly bound to
plasma protein (91–99%). It is metabolized by uridine
diphosphate glucoronyl transferase (UDPGT) in the
liver and gut to inactive furosemide glucoronide. Also
85% of the remainder transports to the kidneys. Since
furosemide is highly protein-bound, it is not well fil-
tered from the glomerulus. Forty two percent of total
furosemide is taken up in the S1 segment of the prox-
imal tubule and metabolized to inactive glucoronide
while the remainder is taken up by the S2 segment
and is secreted in active form into the lumen by the
organic anion transport system [8,10]. The uptake and
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in albumin concentration. Therefore, a low serum al-
bumin concentration enhances furosemide metabolism
and leads to decreased tubular secretion of active
diuretics [10]. The mechanism of action of furosemide
is to inhibit the Na-K-2Cl cotransporter in the lu-
minal membrane of the thick ascending limb of the
loop of Henle [1]. Sodium reabsorption takes place
via the Na-K-2Cl cotransporter (NKCC). Each mol-
ecule of sodium, potassium and chloride binds to
NKCC then transformation of NKCC occurs and
allows a second molecule of chloride to bind and all
of these together will transport into the cell [30].
Furosemide is a competitive inhibitor of the first chloride
molecule, thus inhibition of the transformation of the
transporter leads to impaired sodium and cation reabsorp-
tion in the thick ascending limb of the loop of Henle
resulting in natriuresis [30]. The efficacy of furosemide is
robust compared to other groups of diuretics. Thus, fur-
osemide is a drug of choice in edematous patients as indi-
cated in acute or chronic kidney disease, congestive heart
failure, hepatic cirrhosis and for patients who need natri-
uresis such as in hypertensive patients [1,31-33].
It is well known that the effect of albumin binding
is to trap furosemide in the plasma so it can be deliv-
ered to the kidneys as opposed to being distributed
throughout the body. In the situation of hypoalbumi-
nemia, less furosemide-albumin complex can be deliv-
ered to the kidneys. Moreover, a decline in renal
perfusion (CKD in our study) also decreased the rate
of drug delivery to its site of action. In addition, a low
serum albumin concentration enhanced furosemide
metabolism and lead to decreased tubular secretion of
active diuretics [10]. Another mechanism of albumin
is favouring an enhanced vascular refilling rate which
is able to promote effective reabsorption of fluid accu-
mulation from the interstitial space, thereby inducing
transient retrieval of increased effective circulating
volume. In this manner, an increased renal flow is
propitiated and more efficient glomerular filtration
function and urine output are achieved irrespective of
possible favourable effects on the pharmacodynamics
of furosemide. Taken together, our findings in this study
are compatible with the hypothesis that the added-up
albumin may enhance the rate of furosemide-albumin
complex delivery to the kidneys [9], assist the active me-
tabolite of furosemide to its site of action [10] and
increase renal blood flow leading to more efficient glom-
erular filtration function. The effect of increased intra-
tubular albumin which is found in severe nephrotic
syndrome patients and which might blunt the response
of furosemide was not prominent in our study since all
the patients in our studies had 24-hour urine protein
less than 3.5 g/d.Conclusion
In conclusion, our studies have demonstrated that the
combination of furosemide and albumin have a superior
short-term efficacy over furosemide alone in enhancing
water and sodium diuresis in stable hypoalbuminemic
chronic kidney disease patients.
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